Jiuzhou Pharmaceuticals: In 2026, the company will face fluctuations in gross profit margin due to factors such as the expiry of the patents of major client projects and price increases in raw materials.

On April 24th, Jiuzhou Pharmaceutical Industry stated in a conference call that in 2026, they will face fluctuations in gross profit margins due to factors such as the expiration of patents for major customer projects and increases in raw material prices. The company plans to reduce the negative impact by adding new projects and optimizing production processes.